CCMEDIUM SIGNALFINANCIAL10-K

Chemours significantly reduced share buybacks while facing margin compression despite maintaining operational discipline through lower capital expenditures and debt reduction.

The dramatic reduction in share buybacks from $495M to $69M suggests management is preserving cash in response to operational headwinds, evidenced by declining gross profit margins. However, the company maintained dividend payments with a modest increase, indicating confidence in underlying cash generation capabilities.

Comparing 2026-02-24 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

Chemours faced profitability pressures with gross profit declining to $902M while SG&A expenses rose substantially to $799M, compressing margins significantly. The company responded by dramatically curtailing share repurchases and reducing capital expenditures by 41% to $213M, while also paying down debt by $400M. Despite operational challenges, management maintained dividend commitments with payments increasing modestly to $164M, suggesting disciplined capital allocation focused on financial flexibility.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-86.1%
$495.0M$69.0M

Buyback activity reduced 86.1% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
-40.8%
$360.0M$213.0M

Capex reduced 40.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
+36.6%
$585.0M$799.0M

SG&A up 36.6% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Gross Profit
P&L
-21.6%
$1.2B$902.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Dividends Paid
Cash Flow
+10.8%
$148.0M$164.0M

Dividend payments increased 10.8% — management confidence in sustained cash generation.

Total Debt
Balance Sheet
-10.5%
$4.0B$3.6B

Debt reduced 10.5% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-18
ADDED
As of February 18, 2026, 150,085,308 s hares of the company s common stock, $0.01 par value, were outstanding.
4 The Chemours Company Sustainability At Chemours, our sustainability approach is grounded in our vision to deliver Trusted Chemistry that improves lives and helps communities to thrive and is tightly integrated with our Pathway to Thrive strategy.
Our work in sustainability creates value for our shareholders by protecting our privilege to operate, differentiating our portfolio in a competitive market, meeting the needs of our customers, building resilience for the future, and ultimately helping to advance our Pathway to Thrive strategy.
Our Trusted Chemistry vision serves as the foundation for our Corporate Responsibility Commitment ("CRC") goals.
We measure and report our progress against these goals transparently in our Annual Sustainability Report to ensure accountability and impact.
+7 more — sign up free →
REMOVED
As of February 12, 2025, 149,440,788 s hares of the company s common stock, $0.01 par value, were outstanding.
4 The Chemours Company Sustainability At Chemours, our approach to Sustainability begins with our vision to deliver Trusted Chemistry that helps people live better lives and communities to thrive.
In 2018, we set forth ambitious Corporate Responsibility Commitment ("CRC") goals that we aim to achieve by 2030.
These goals are designed to promote accountability and enable us to measure and transparently report the progress and impact of our sustainability commitment.
Leveraging a robust governance framework, we are working to integrate sustainability across our organization and our business management processes.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →